Industrial process for the preparation of high purity estetrol

Patent metadata

Field	Value
Publication number	US-11633406-B2
Application number	US-202017639206-A
Country	US
Kind code	B2
Filing date	Sep 2, 2020
Priority date	Sep 3, 2019
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

The invention relates to the preparation of estetrol of formula (I), derivatives thereof protected at positions 3,15α,16α,17β of general formula (III), and 3-hydroxy derivatives thereof protected at positions 15α,16α,17β of general formula (IV), and to the intermediates of general formulae (III) and (IV) applied in the process. Another aspect of the invention is the use of estetrol of formula (I) obtained by the process of the invention for the preparation of a pharmaceutical composition.

First claim

The invention claimed is:

1. Process for the preparation of estetrol of formula (I),

starting from the compound of formula (II)

wherein the process comprises:
(a) acylating a compound of formula (II) in a suitable solvent using a suitable reactant to give a compound of general formula (III);

wherein R=methyl group or hydrogen;
(b) of removing a benzyl protecting group in position 3 by transfer hydrogenation or catalytic hydrogenation to give a compound of general formula (IV)

wherein R=methyl group or hydrogen; and
(c) deprotecting the compound of formula (IV) in an alkaline medium with an alkali metal carbonate, alkali metal hydrogen carbonate, or alkali metal hydroxides in a suitable solvent.

2. The process according to claim 1 , wherein the solvent used in step (a) is selected from the group consisting of aliphatic and aromatic hydrocarbons, halogenated hydrocarbons, esters, and ethers.

3. The process according to claim 1 , wherein the reactant used in step (a) is acetic anhydride, acetyl chloride, acetyl bromide, or acetic acid-formic acid mixed anhydride.

4. The process according to claim 1 , wherein step (a) is carried out in the presence of a tertiary amine base.

5. The process according to claim 1 , wherein step (a) further comprises crystallizing the resulting compound of general formula (III) from C 1-3 alcohols.

6. The process according to claim 1 , wherein step (a) is carried out without the purification and/or isolation of the compounds of formula (II).

7. The process according to claim 1 , wherein step (b) is carried out by catalytic hydrogenation with hydrogen gas, wherein the catalyst is selected from palladium or palladium on a support.

8. The process according to claim 7 , wherein the catalytic hydrogenation uses a solvent selected from the group consisting of alcohols, esters, and ketones.

9. The process according to claim 1 , wherein step (b) is carried out by transfer hydrogenation using a cyclohexene reagent.

10. The process according to claim 9 , wherein the transfer hydrogenation uses an alcohol solvent.

11. The process according to claim 1 , wherein step (b) further comprises crystallizing the resulting compound of general formula (IV) from esters, hydrocarbons, alcohols, or mixtures thereof.

12. The process according to claim 1 , wherein the solvent used in step (c) is selected from the group consisting of water, an alcoholic solvent, or a mixture thereof.

13. The process according to claim 1 , wherein the step (c) is carried out in the presence of an alkali metal carbonate, an alkali metal hydrogen carbonate, an alkali metal alcoholate, or an alkali metal hydroxide.

14. The process according to claim 1 , wherein R is a methyl group.

15. The process according to claim 1 , wherein R is hydrogen.

16. A compound selected from the group consisting of (15α,16α,17β)-3-(benzyloxy)estra-1,3,5(10)-triene-15,16,17-triyltriacetate, (15α,16α,17β)-3-(benzyloxy)estra-1,3,5(10)-triene-15,16,17-triyl triformiate, and (15α,16α,17β)-3-hydroxyestra-1,3,5(10)-triene-15,16,17-triyl triformiate.

Assignees

• Richter Gedeon Nyrt

Inventors

• Lovas Róbert
• Mahó Sándor
• Bacsa Ildikó
• Mayer Beatrix

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/565 Primary

  not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61P15/18

  Feminine contraceptives · CPC title

• C07J75/00

  Processes for the preparation of steroids in general · CPC title